Torrent Pharma Q1 revenue jumps 55% after JB Pharma acquisition; PAT rises 3.3%

Torrent Pharmaceuticals reported Q1 FY27 revenue of ₹4,921 crore, up 55% year-on-year, aided by JB Pharma. Profit after tax rose 3.3% to ₹566 crore as integration, depreciation and higher finance costs weighed on earnings. India revenue grew 19%.

— Source publishedThu, 30 Jul, 2026, 18:33 IST·First seen Thu, 30 Jul, 2026, 19:18 IST·Source The Hindu BusinessLine

What happened

Torrent Pharmaceuticals · Torrent Pharma’s FY27 first-quarter revenue rose 55% following JB Pharma’s acquisition, while PAT grew 3.3% as integration,

Key facts

  • Consolidated PAT: ₹566 crore, up 3.3% YoY
  • Revenue from operations: ₹4,921 crore, up 55%
  • Operating EBITDA: ₹1,664 crore, up 61%; margin 33.8% versus 32.5%
  • Exceptional expenses: ₹21 crore
  • Ex-JB Pharma revenue: ₹3,720 crore, up 17%
  • India revenue: ₹2,157 crore, up 19%
  • US revenue: up 36%
  • Brazil revenue: up 27%
  • JB Pharma revenue: ₹1,201 crore, up 10%; EBITDA ₹424 crore, up 34%
  • Generic Semaglutide market share: 36%

Why this matters

JB Pharma has materially accelerated Torrent’s revenue base, offering early strategic validation of the acquisition even as integration and financing expenses temporarily constrain profit conversion.

What to watch

  • Quarterly EBITDA margin and PAT growth relative to the 55% revenue-growth base.
  • Sequential finance-cost, depreciation and amortization trends following the acquisition.
  • Net debt-to-EBITDA, interest coverage and operating-cash-flow conversion.
  • India revenue growth versus the 19% Q1 rate and prescription-market-share movement.
  • Management disclosure on realized versus targeted JB Pharma synergies.
  • Any manufacturing, regulatory or product-portfolio disruptions during integration.
  • Prioritize cross-selling JB Pharma brands through Torrent's India distribution and medical-representative network.
  • Consolidate procurement, manufacturing planning, administration and overlapping sales infrastructure to extract acquisition synergies.
  • Use operating cash flow to reduce acquisition-related borrowings and contain finance-cost growth.
  • Defend India prescription-market share while expanding chronic-therapy and branded-generic portfolios.
  • Provide clearer guidance on integration milestones, synergy run rate, leverage and margin normalization.